Potential use of non-classical pathways for the transport of macromolecular drugs.
Since an increasing number of drug delivery strategies utilising proteins and peptides exhibiting 'non-classical' transport activities have been proposed, studies have begun to establish underlying functional relationships between different vectors. These attempts to find common factors have been hampered by a lack of biophysical data for the various potential protein and peptide transporters, as well as by the structural and functional diversity of the group as a whole. We describe the various types of vectors being considered for use and the preliminary therapeutic successes that have been achieved. Additionally, the various models that have been proposed for non-classical import and export are outlined and discussed in relation to therapeutic delivery. Possible future developments are also discussed.
Kueltzo
L A
LA
University of Kansas, Department of Pharmaceutical Chemistry, 2095 Constant Avenue, Lawrence, KS 66047, USA.
Middaugh
C R
CR
D000818:Animals; D002352:Carrier Proteins / Q000493:pharmacokinetics*; D016503:Drug Delivery Systems / Q000379:methods*; D015696:Gene Products, tat / Q000493:pharmacokinetics*; D005822:Genetic Vectors / Q000493:pharmacokinetics*; D006801:Humans; D046911:Macromolecular Substances; D010455:Peptides / Q000493:pharmacokinetics*; D011506:Proteins / Q000493:pharmacokinetics
D002352:Carrier Proteins; D015696:Gene Products, tat; D046911:Macromolecular Substances; D010455:Peptides; D011506:Proteins